TEVA

Drugmaker Eli Lilly & Co (NYSE:LLY) will have to pay $176.5 million to Teva Pharmaceuticals (NYSE:TEVA) as a Boston federal court jury ruled that Lilly’s migraine drug Emgality violated three Teva patents. Notably, Lilly has been accused of violating rights relating to Teva’s migraine drug, Ajovy. Also, the jury found that Lilly willingly infringed the patents. As per a Reuters report, Lilly is not satisfied with the jury’s ruling and strongly believes that it will "ultimately prevail" in the case. Further, it noted that the trial result does not affect its ability to offer Emgality to patients.
https://www.tipranks.com/news/eli-lilly-nyselly-loses-migraine-drug-patent-trial-to-teva?utm_source=advfn.com&utm_medium=referral